CASE REPORT

Hiroshi Matsufuji · Takeki Nishio · Ryota Hosoya

Successful treatment for intractable chylous ascites in a child using a peritoneovenous shunt

Accepted: 23 January 2006 / Published online: 14 February 2006 © Springer-Verlag 2006

Abstract Intractable post-operative chylous ascites had been managed successfully using a peritoneovenous shunt (PVshunt). A 4-year-old girl with neuroblastoma originated from the right adrenal gland was admitted to our hospital. Following the preoperative chemotherapy, tumor resection, and lymph node dissection of the abdominal paraaortic region were carried out. Postoperative radiation therapy 9.6 gray to the tumor bed and to the paraaortic region and a high dose chemotherapy supported by auto bone marrow transplantation were completed. Three months later some enlarged lymph nodes along the duodeno-hepatic ligament were detected and these had gradually increased in size. Lymph node dissection along the hepatic artery and the abdominal aorta was carried out. Pathological examination of the specimen showed reactive lymph node swelling. Chylous ascites developed several days after surgery. Despite the medium-chain triglycerides meal or total parental nutrition, the ascites persisted for more than 80 days. Multiple paracenteses were mandatory. A PV shunt was implanted and the ascites was resolved by the fourth post-operative day. Thirty months later, the vascular end tube of the shunt was ligated. As ascites had not accumulated for 2 weeks, the PV shunt was removed. The patient has been doing well without recurrence of ascites or neuroblastoma for 12 years. As PV shunts were mostly used for long lasting disease, it has not been referred as to how to know when the shunt

H. Matsufuji (🖂)

Department of Pediatric Surgery, St Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, 104-8560, Tokyo, Japan E-mail: matufuhi@luke.or.jp Tel.: +81-3-35415151 Fax: +81-3-5440649

T. Nishio

Department of Surgery, St Luke's International Hospital, Chuo-ku, 104-8560, Tokyo, Japan

R. Hosoya

Department of Pediatrics, St Luke's International Hospital, Chuo-ku, 104-8560, Tokyo, Japan

should be removed. If the shunt is inserted for transient management of ascites, less invasive methods of investigation to know when to remove the shunt need to be developed.

Keywords Chylous · Ascites · Peritoneovenous shunt · Child

Introduction

It has been reported that chylothorax or chyloperitoneum in children developed in many pathological conditions, such as congenital lymphatic disorders, thoracocardiac operation, abdominal surgery, malignancy, trauma, liver cirrhosis, radiation therapy in the pelvic space, peritoneal dialysis, and abdominal tuberculosis [1]. While spontaneous recovery has occurred in most post-operative chylous effusions, repeated paracenteses may cause considerable loss of calories, protein, and lymphocytes. A case with intractable post-operative chylous ascites successfully managed using a peritoneovenous shunt (PV shunt) is reported.

Case report

A 4-year-old girl with neuroblastoma was admitted to our hospital. The radiological evaluation showed a huge calcificated right adrenal tumor invading the liver and paraaortic lymph node swelling. Further evaluations did not show any distant metastasis including bone, bone marrow, lung, or brain. Following the preoperative chemotherapy with cyclophosphamide (CPA), vincristine (VCR), adriamicine (ADR) and *cis*-platinum (CDDP), tumor resection, and lymph node dissection of the abdominal paraaortic region were carried out. Postoperative chemo-radiotherapy was performed. Radiation (9.6 gray) to the tumor bed, paraaortic area and high-dose chemotherapy of CDDP, VP-16, and melphalane supported by auto bone marrow transplantation were completed. The patient demonstrated good tolerance, recovered from the bone marrow suppression, and was discharged from the hospital. Total doses of the agents administered were as follows: VCR 3.0 mg/m^2 , CPA 2,500 mg/m², CDDP 460 mg/m2, ADR 245 mg/ m^2 , VP-16 200 mg/m², melphalan 180 mg/m². Three months later, some enlarged lymph nodes along the duodeno-hepatic ligament were detected by abdominal ultrasound echogram (ECHO) and these gradually increased in size. Lymph node dissection along the hepatic artery and abdominal aorta was carried out again. Pathological examination of the resected specimen showed reactive lymph node swelling without evidence of malignancy. The patient complained abdominal fullness, pain, and nausea several days after operation. Physical examination showed a notable abdominal distension and fluctuation. Abdominal ECHO detected a considerable amount of ascites and abdominal paracentesis was performed. The analysis of evacuated ascites showed the following: specific gravity 1.034, chylomicrone (+), cell count 6,000/mm³, lymphocyte 85%, and monocyte 11%. While the medium-chain triglycerides (MCT) meal or total parental nutrition (TPN) was administered, the ascites persisted for 80 days. Repeated paracenteses were mandatory and a considerable amount of fresh frozen plasma needed to be supplied. As both the cytological examination for malignant cells and the bacterial examination were negative, the evacuated ascites was re-infused through the central venous access. Neither cardiac congestion nor disseminated intravascular coagulation (DIC) nor sepsis developed. A PVshunt (Denver Biomaterials Inc, Evergreen, CO) was implanted. The vascular end tube was placed in the superior vena cava through the right internal jugular vein. The ascites was resolved by the fourth post-operative day. The patient was subsequently discharged on the seventh day after shunt implantation. As ascites had not developed for 20 months after the implantation, radiological studies were performed to evaluate if the shunt was patent and functioning. While the abdominal ECHO did not show accumulation of ascites, the radiopaque material, which was injected into the shunt tube using a fine needle, moved to the central vein in a few minutes. Ten months later, the vascular end tube of the shunt was ligated. As ascites had not accumulated over 2 weeks, the shunt was removed. Neither ascites nor recurrence of neuroblastoma has been observed for 12 years. And the patient has been doing well.

Discussion

Post-operative chylous effusion results from injury of the thoracic duct, cistena chyli, or its intestinal tributaries. While chylous ascites may develop after operation for lymphangioma, abdominal aortic surgery, or lymph node dissection in the retroperitoneal space, it is likely to subside spontaneously. Blalock [2] reported that for the lymphatic leakage to persist, not only injury of the thoracic duct but also impairment of the collateral pathway formation must be present. Two cases with chylous ascites after radiation therapy or chemotherapy were reported. In one case, the chylous ascites persisted after the retroperitoneal lymph node dissection and two courses of post-operative dactinomycine therapy [3]. Another case had a combined treatment of radiation and chemotherapy [4]. In the presented case, the radiation and the multi-agent chemotherapy before the second lymph node dissection might impair healing of the injured lymphatics and formation of a collateral circuit.

Although most of the patients with post-operative chylous effusion were managed by paracentesis, MCT milk, low fatty acid meal or TPN successfully, surgical treatment such as ligature of the injured lymphatics or a PV shunt was indicated on some occasions. While many cases of successful ligation have been reported, usually it is difficult to locate the leaking lymphatics during the operation. The literature review of case reports revealed 17 cases of children under 12 years who underwent implantation of a PV shunt (Table 1) [5-17]. Seven shunts in four patients were obstructed before ascites was resolved. All of these children had congenital lymphatic disorders and chylous ascites. High levels of cell counts and protein contents in the chylous ascites increase the risk of shunt obstruction. Denver shunt has a valve mechanism, which prevents back flow of blood and the valve chamber lies in the subcutaneous tissue can be compressed to promote flow and to relieve blockage. Other complications reported were cardiac congestion, DIC, sepsis, nephritis, dissemination of malignant cells, and perforation of the coronary sinus. Shunting for malignant ascites has a higher incidence of DIC and malignant cells dissemination. In the reported case, both the pathological examination of the dissected lymph nodes and analysis of the ascites were negative for malignant cells or bacteria. The evacuated ascites had been infused to the central vein before the shunting operation. As any serious complication such as sepsis, DIC or pulmonary congestion had not developed, the shunt was inserted. Ascites had been controlled well without complications. Sooriakumaran et al. [18] reviewed 11 children who underwent shunting over a 17year period. In all of the children ascites resolved except for a child of 4 years old with lymphohistiocytosis. Since PV shunts had been used mostly in adults with chronic disease, it has not been referred how to know when the shunt should be removed [19, 20]. Sooriakumaran et al. [18] recommended elective removal of the shunt after 1 year as five shunts were removed 1-3 years after insertion without recurrence of ascites. In the presented case, ascites had not accumulated for 20 months and the shunt was still patent and functioning [20, 21]. We ligated the infusion catheter and observed the patient for 2 weeks to confirm whether ascites should be managed without a shunt. A PV shunt is recommended in the management of ascites unresponsive to medical treatment. If the shunt is inserted for transient management of the ascites, less invasive

Table 1 Case reports of a	a peritoneovenous s	shunt in children
---------------------------	---------------------	-------------------

Case	References	Age	Sex	Etiology of ascites	Character of ascites	Duration of shunting	Complication
1	Klein [5]	1 Y	F	Budd-Chiari synd.	Serous	15 months	_
2	Chang [6]	12 Y	Μ	Lymphangiomatosis	Chylous	6 months	Obstruction
3	Altman [7]	10 M	Μ	Biliary atresia	Serous	?	?
4	Ryan [8]	10 Y	F	Multiple hygromas	Chylous	24 months	Obstruction
					Chylous	> 16 months	Obstruction
5	Guttmann [9]	7 W	М	Generalized lymphatic malformation	Chylous	10 days	Obstruction
6	Guttmann	6 Y	Μ	Generalized lymphatic	Chylous	1 month	Obstruction
				malformation	Chylous	1 month	Obstruction
					Chylous	5 month	Obstruction
7	Press [10]	2 Y	F	Congenital lymphangioectasia	?	?	?
8	Shah [11]	2 Y	М	Liver cirrhosis	Serous	1 day	Coronary sinus perforation
9	Man [12]	7 M	М	Idiopathic	Chylous	>4 years	_ _
10	Man	5 M	F	Hepatitis liver cirrhosis	Chylous	> 6 months	_
11	Man	4 Y	F	Peritonitis carcinomatosis	Chylous	2.5 months	_
12	Man	9 Y	F	Wilms' tumor post-op	Chylous	?	_
13	Kerr [13]	7 Y	Μ	Leukemia	Chylous	> 9 months	_
14	Salacedo [14]	9 Y	F	Hepatitis	Serous	8 weeks	DIC, congestion, nephritis, sepsis
15	Gracia [15]	Neonate	F	Budd-Chiari synd.	Serous	> 30 months	Congestion
16	Gillan [16]	6 W	Μ	Hepatitis	Serous	2 months	_
17	Pettitt [17]	Neonate	Μ	Lymphatic malformation	Serous	>6 months	-
18	Presented case	5 Y	F	Neuroblastoma post-op	Chylous	30 months	-

Y years old, M months old, W weeks old, F female, M male

methods of investigation to know when to remove the shunt need to be developed.

References

- 1. Browse NL, Wilson NM, Russo F (1992) Aetiology and treatment of chylous ascites. Br J Surg 79:1145–1150
- Blalock A, Robinson CS, Cunningham RS (1937) Experimental studies on lymphatic blockage. Arch Surg 34:1049–1071
- Jayabose S, Kogan S, Berezin S (1989) Combined occurence of chyloperitoneum and chylothorax after surgery and chemotherapy for Wilm's tumor. Cancer 64:1790–1795
- 4. Rao SSC, Dundas S, HoldsworthCS (1987) Intestinal lymphangioectasia secondary to radiotherapy and chemotherapy. Dig Dis Sci 32:939–942
- Klein MD, Philippart AI (1979) Posttraumatic Budd-Chiari syndrome with late reversibility of hepatic venous obstruction. J Pediatr Surg 14:661–663
- Chang JH, Newkrik J, Carlton G (1980) Generalized lymphangiomatosis with chylous ascites; Treatment by peritoneovenous shunting. J Pediatr Surg 15:748–750
- 7. Altman RP, Carvett CM (1981) The retroperitoneal approach for peritoneal venous shunting. J Pediatr Surg 16:965–966
- Ryan JA, Smith MD, Page CP (1981) Treatment of Chylous ascites with peritoneo-venous shunt. Ann Surg 47:384–386
- Gutmann FM, Montupet P, Bloss RS (1982) Experience with peritoneo-venous shunting for congenital chylous ascites in infants and children. J Pediatr Surg 17:368–372

- Press OW, Press NO, Kaufman SD (1982) Evaluation and management of chylous ascites. Ann Intern Med 96:358–364
- Shah FH, Stulc JP, Hoy GR (1982) Coronary sinus perforation of a LeVeen shunt in a child. Chest 2:197–199
- Man DWK, Spitz L (1985) The treatment of chylous ascites in children. J Pediatr Surg 120:72–75
- Kerr RSC, Powis SJA, Ross JRY (1985) Peritoneovenous shunt in the management of paediatric chylous ascites. Br J Surg 72:443–444
- Salacedo JR, Sorkin L(1985) Nephritis associated with an infected peritoneal venous LeVeen shunt. J Pediatr Gastroenterol Nutr 4:842–844
- Gracia VF, Howell CG Barbot D (1985) Small tube peritoneovenous shunting for the management of neonatal intractable ascites. Surg Gynecol Obstet 169:273–274
- Gillan GL, Stokes KB, MCLellan J (1980) Fluminant hepatic failure with intractable ascites due to an Echovirus 11 infection successfully managed with a peritoneo-venous (LeVeen) shunt. J Pediatr Gastroenterol Nutr 5:476–480
- 17. Pettitt BJ (1992) Use of a modified Denver peritoneal shunt in a new born with intractable ascites. J Pediatr Surg 27:108–109
- Sooriakumaran P, McAndrew HF, Kiely EM (2005) Peritoneal shunting is an effective treatment for intractable ascites. Postgrad Med J 81:259–261
- LeVeen HH, Christoudias G, Iq M (1974) Peritoneo-venous shunting for ascites. Ann Surg 180:580–586
- Klepetko W, Miholic J, Muller C (1987) Diagnosis of peritoneal venous shunt occlusion. Langenbecks Arch Chir 371:39–48
- Algeo MJH, Powell M, Couacaud J (1987) LeVeen shunt visualization without function using Technetium-99 m macroaggregate albumin. Clin Nucl Med 12:741–743